Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Vanda Pharmaceuticals Inc VNDA

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI... see more

Opinion & Analysis (NDAQ:VNDA)

No current opinion is available.

Bullboard Posts (NDAQ:VNDA)

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA): A Diversified Biop

http://beyondspx.com/2024/08/02/vanda-pharmaceuticals-inc-nasdaqvnda-a-diversified-biopharma-poised-for-growth/
MikeTester - August 3, 2024

$VNDA -Settlement

$VNDA -On May 19, 2022, Vanda Pharmaceuticals agreed to settle a securities fraud class action complaint (the “Complaint”) for $11.5...
JGrabar - May 31, 2022

RE: RE: i guess many MISSED this one ??LOL

So did I ..... I missed Vanda's run WOW ! I also hold a Jr Pharma named Pharmagap Inc.I’m a shareholder...
bullorbear22 - July 5, 2009

RE: i guess many MISSED this one ??LOL

It's not too late - buy some now.  Haha just kidding, don't feel bad I missed it too.
jjwilson - May 7, 2009

Consensus target at $40

Three analysts have 12-mo. price targets on this company with a consensus view of around $40 ($35, $40, and $44), yet now it seems to...
moneystud - March 14, 2007

Podcasts